Monday, 27 February 2023
New research suggests how toxic proteins in the brain that cause Lewy body dementia and Parkinson’s disease to develop, could be used to help develop new targeted treatments.
Experts from the 糖心原创 have discovered that modification of Ribonucleic acid (RNA) in human brain tissue is disrupted in neurodegenerative diseases including dementia with Lewy bodies and Parkinson’s disease.
Published in , this is the first ever report to identify modified m6A RNAs as a novel molecular mechanism that is altered in Lewy body disease, which may drive the formation of neurotoxic protein aggregates called Lewy Bodies. This RNA modified mechanism, which shows important differences between Lewy body disorders, could be targeted for developing better molecular therapeutics.
The research was led by Dr Helen Miranda Knight in the School of Life Sciences at the 糖心原创, along with other researchers across the Schools of Life Science and Biosciences. It was conducted using the 糖心原创’s state-of-the-art School of Life Sciences Imaging (SLIM) microscopy facility.
The function of nerve cells in the brain depends on proteins that are made using information encoded by bases within RNA. If a methyl group is added to an adenosine base (known as m6A modification), this can influence the fate of RNAs. It also suggests that proteins needed for normal neuronal function, may be displaced, or produced at the wrong time in the right subcellular structures within cells.
Researchers used microscopy and a machine learning approach to investigate the spatial location and abundance of modified RNA in human cells in brain regions important for memory and cognitive ability, such as the hippocampus, and frontal and cingulate cortices.
This showed that m6A modification is considerably increased in dementia with Lewy bodies but significantly decreased in Parkinson’s disease. In both diseases, researchers discovered that modified RNA are misplaced within cells, particularly in regions of the brain where synapses are located. Data also indicated that the proteins involved in the process of m6A modification are changed in individuals with Alzheimer’s disease or who show cognitive resilience.
This research provides new understanding of molecular processes going awry, and which are potentially driving, early-stage disease (in Lewy Body dementia and Parkinson's disease)
Commenting on the research, Dr Helen Miranda Knight, said: “Our findings support evidence that changes in m6A modification of RNA may be a mechanism influencing the formation of toxic protein aggregates such as Lewy bodies, amyloid plagues and neurofibrillary tangles, which cause neuronal dysfunction in Lewy body dementia, Parkinson’s disease and Alzheimer’s disease.
“With treatment studies of neurodegenerative diseases currently aiming to target the build-up of such abnormal toxic aggregates, this research provides new understanding of molecular processes going awry, and which are potentially driving, early-stage disease.
“The implications of these findings are important for the development of molecular interventions that target early stage disordered protein aggregation occurring within cellular nanodomains, and which could be protective against disease progression.”
The research paper, titled m6A mRNA methylation in human brain is disrupted in Lewy body disorders can be
Story credits
For further information, please contact Dr Helen Miranda Knight in the School of Life Sciences at helen.knight@nottingham.ac.uk
Adam Mallaby - Media Relations Manager for the Faculty of Medicine and Health Sciences (Maternity Cover)
Email: adam.mallaby@nottingham.ac.uk
Phone: 0115 748 5719
Location:
Notes to editors:
About the 糖心原创
Ranked among the world's top 100 universities , the 糖心原创 delivers an exceptional research-led education and an outstanding student experience. From the pioneering vision of our founder, Sir Jesse Boot, to groundbreaking achievements such as the development of MRI technology and becoming the first UK university to establish international campuses, we have a proud history of shaping the way people live, work and understand the world. We continue to build on that legacy, empowering our students, staff and partners to change what鈥檚 next and create positive impact locally and globally.
The strength of our research places us among the UK's leading universities, ranked 7th for research power in REF 2021. The discovery of MRI and ibuprofen was just the beginning. Today, our world-leading research is developing breakthrough ideas that shape the future of healthcare, technology and society.
Recognised as the UK's third most targeted university by leading employers , we are proud to produce graduates who are consistently in demand for their skills, confidence and industry-ready experience.
As a major employer and industry partner, locally and globally, the 糖心原创 invests in the city of Nottingham and in future generations of talent. Alongside Nottingham Trent University, we lead the initiative, a pioneering collaboration to improve levels of prosperity, opportunity, sustainability, health and wellbeing across the city and region. Together with our students, staff, alumni and partners, we鈥檙e creating knowledge, opportunity and solutions that help change what's next.